Subscribe
deimagine
deimagine / iStockphoto.com
25 August 2017Americas

Cantor Colburn tops list of law firms overturning Myriad rejections

Law firm Cantor Colburn has achieved the highest rate of successful allowances for patent applications following section 101 rejections citing the Mayo and Myriad precedents, according to data compiled by research firm Juristat.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Cantor Colburn adds new chair to life sciences group
19 July 2018   US-based law firm Cantor Colburn has hired Bryan Zerhusen as a partner and chair of the firm’s life sciences practice group.
Americas
US Supreme Court strikes Myriad blow
13 June 2013   The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Cantor Colburn adds new chair to life sciences group
19 July 2018   US-based law firm Cantor Colburn has hired Bryan Zerhusen as a partner and chair of the firm’s life sciences practice group.
Americas
US Supreme Court strikes Myriad blow
13 June 2013   The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

More on this story

Americas
Cantor Colburn adds new chair to life sciences group
19 July 2018   US-based law firm Cantor Colburn has hired Bryan Zerhusen as a partner and chair of the firm’s life sciences practice group.
Americas
US Supreme Court strikes Myriad blow
13 June 2013   The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?